nodes	percent_of_prediction	percent_of_DWPC	metapath
Gadoxetate—ABCC2—esophageal cancer	0.413	1	CbGaD
Gadoxetate—ABCC3—Cisplatin—esophageal cancer	0.103	0.231	CbGbCtD
Gadoxetate—ABCC3—Methotrexate—esophageal cancer	0.0672	0.15	CbGbCtD
Gadoxetate—SLCO1B3—Methotrexate—esophageal cancer	0.0596	0.133	CbGbCtD
Gadoxetate—ABCC2—Carboplatin—esophageal cancer	0.055	0.123	CbGbCtD
Gadoxetate—ABCC4—Methotrexate—esophageal cancer	0.0513	0.114	CbGbCtD
Gadoxetate—ABCC2—Cisplatin—esophageal cancer	0.047	0.105	CbGbCtD
Gadoxetate—SLCO1B1—Methotrexate—esophageal cancer	0.0347	0.0774	CbGbCtD
Gadoxetate—ABCC2—Methotrexate—esophageal cancer	0.0305	0.068	CbGbCtD
Gadoxetate—Oral discomfort—Capecitabine—esophageal cancer	0.0036	0.0521	CcSEcCtD
Gadoxetate—Venous thrombosis—Carboplatin—esophageal cancer	0.00356	0.0515	CcSEcCtD
Gadoxetate—Fluid overload—Carboplatin—esophageal cancer	0.00309	0.0447	CcSEcCtD
Gadoxetate—Extravasation—Carboplatin—esophageal cancer	0.0022	0.0318	CcSEcCtD
Gadoxetate—Bronchopneumonia—Capecitabine—esophageal cancer	0.0019	0.0275	CcSEcCtD
Gadoxetate—Tetany—Cisplatin—esophageal cancer	0.00173	0.025	CcSEcCtD
Gadoxetate—Phlebitis—Carboplatin—esophageal cancer	0.00162	0.0234	CcSEcCtD
Gadoxetate—Venous thrombosis—Cisplatin—esophageal cancer	0.00104	0.0151	CcSEcCtD
Gadoxetate—Fluid overload—Cisplatin—esophageal cancer	0.000905	0.0131	CcSEcCtD
Gadoxetate—Swelling face—Capecitabine—esophageal cancer	0.000871	0.0126	CcSEcCtD
Gadoxetate—Intestinal perforation—Methotrexate—esophageal cancer	0.000781	0.0113	CcSEcCtD
Gadoxetate—Venous thrombosis—Capecitabine—esophageal cancer	0.000769	0.0111	CcSEcCtD
Gadoxetate—Sneezing—Capecitabine—esophageal cancer	0.000749	0.0109	CcSEcCtD
Gadoxetate—Necrosis—Cisplatin—esophageal cancer	0.000717	0.0104	CcSEcCtD
Gadoxetate—Abscess—Cisplatin—esophageal cancer	0.000711	0.0103	CcSEcCtD
Gadoxetate—Infection—Carboplatin—esophageal cancer	0.00068	0.00985	CcSEcCtD
Gadoxetate—Respiratory distress—Capecitabine—esophageal cancer	0.000653	0.00946	CcSEcCtD
Gadoxetate—Tenderness—Cisplatin—esophageal cancer	0.000645	0.00934	CcSEcCtD
Gadoxetate—Extravasation—Cisplatin—esophageal cancer	0.000645	0.00934	CcSEcCtD
Gadoxetate—Cellulitis—Cisplatin—esophageal cancer	0.000619	0.00896	CcSEcCtD
Gadoxetate—Intestinal obstruction—Capecitabine—esophageal cancer	0.000609	0.00881	CcSEcCtD
Gadoxetate—Ulcer—Cisplatin—esophageal cancer	0.000595	0.00862	CcSEcCtD
Gadoxetate—Body temperature increased—Carboplatin—esophageal cancer	0.000541	0.00784	CcSEcCtD
Gadoxetate—Fluid retention—Cisplatin—esophageal cancer	0.000534	0.00774	CcSEcCtD
Gadoxetate—Coagulopathy—Capecitabine—esophageal cancer	0.000533	0.00772	CcSEcCtD
Gadoxetate—Tingling sensation—Capecitabine—esophageal cancer	0.000516	0.00747	CcSEcCtD
Gadoxetate—Injection site pain—Capecitabine—esophageal cancer	0.000508	0.00736	CcSEcCtD
Gadoxetate—Phlebitis—Cisplatin—esophageal cancer	0.000474	0.00687	CcSEcCtD
Gadoxetate—Cellulitis—Capecitabine—esophageal cancer	0.000456	0.00661	CcSEcCtD
Gadoxetate—Hypocalcaemia—Capecitabine—esophageal cancer	0.000453	0.00656	CcSEcCtD
Gadoxetate—Cardiac failure congestive—Cisplatin—esophageal cancer	0.000451	0.00652	CcSEcCtD
Gadoxetate—Renal failure acute—Cisplatin—esophageal cancer	0.000443	0.00641	CcSEcCtD
Gadoxetate—ABCC4—Platelet degranulation—PFN1—esophageal cancer	0.00044	0.00641	CbGpPWpGaD
Gadoxetate—Ulcer—Capecitabine—esophageal cancer	0.000439	0.00635	CcSEcCtD
Gadoxetate—Cyanosis—Methotrexate—esophageal cancer	0.000436	0.00632	CcSEcCtD
Gadoxetate—ABCC4—NRF2 pathway—BLVRB—esophageal cancer	0.000436	0.00634	CbGpPWpGaD
Gadoxetate—ABCC3—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.000435	0.00634	CbGpPWpGaD
Gadoxetate—Anaphylactoid reaction—Cisplatin—esophageal cancer	0.000422	0.00611	CcSEcCtD
Gadoxetate—ABCC4—Response to elevated platelet cytosolic Ca2+—PFN1—esophageal cancer	0.000419	0.0061	CbGpPWpGaD
Gadoxetate—Cerebrovascular accident—Cisplatin—esophageal cancer	0.000417	0.00604	CcSEcCtD
Gadoxetate—Blood pressure increased—Capecitabine—esophageal cancer	0.000415	0.00601	CcSEcCtD
Gadoxetate—ABCC3—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.000415	0.00604	CbGpPWpGaD
Gadoxetate—ABCC2—NRF2 pathway—ALDH3A1—esophageal cancer	0.000413	0.006	CbGpPWpGaD
Gadoxetate—Injection site reaction—Capecitabine—esophageal cancer	0.000412	0.00597	CcSEcCtD
Gadoxetate—ABCC3—ABC-family proteins mediated transport—ABCB1—esophageal cancer	0.000396	0.00577	CbGpPWpGaD
Gadoxetate—Face oedema—Cisplatin—esophageal cancer	0.000394	0.00571	CcSEcCtD
Gadoxetate—ABCC3—NRF2 pathway—PRDX1—esophageal cancer	0.000394	0.00574	CbGpPWpGaD
Gadoxetate—Fluid retention—Capecitabine—esophageal cancer	0.000394	0.0057	CcSEcCtD
Gadoxetate—Necrosis—Methotrexate—esophageal cancer	0.000394	0.0057	CcSEcCtD
Gadoxetate—Abscess—Methotrexate—esophageal cancer	0.00039	0.00565	CcSEcCtD
Gadoxetate—Irritability—Cisplatin—esophageal cancer	0.00039	0.00565	CcSEcCtD
Gadoxetate—Blood creatinine increased—Cisplatin—esophageal cancer	0.000383	0.00554	CcSEcCtD
Gadoxetate—Dehydration—Cisplatin—esophageal cancer	0.00038	0.0055	CcSEcCtD
Gadoxetate—ABCC4—ABC-family proteins mediated transport—ABCB1—esophageal cancer	0.000373	0.00542	CbGpPWpGaD
Gadoxetate—Hypokalaemia—Cisplatin—esophageal cancer	0.000372	0.00538	CcSEcCtD
Gadoxetate—ABCC4—NRF2 pathway—PRDX1—esophageal cancer	0.000371	0.00539	CbGpPWpGaD
Gadoxetate—ABCC2—NRF2 pathway—BLVRB—esophageal cancer	0.000368	0.00535	CbGpPWpGaD
Gadoxetate—Sepsis—Capecitabine—esophageal cancer	0.00036	0.00521	CcSEcCtD
Gadoxetate—ABCC4—Platelet degranulation—CFL1—esophageal cancer	0.000357	0.00519	CbGpPWpGaD
Gadoxetate—Extravasation—Methotrexate—esophageal cancer	0.000354	0.00513	CcSEcCtD
Gadoxetate—ABCC3—NRF2 pathway—SLC39A6—esophageal cancer	0.000351	0.00511	CbGpPWpGaD
Gadoxetate—Phlebitis—Capecitabine—esophageal cancer	0.00035	0.00506	CcSEcCtD
Gadoxetate—ABCC2—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.000345	0.00502	CbGpPWpGaD
Gadoxetate—Sweating increased—Cisplatin—esophageal cancer	0.000344	0.00498	CcSEcCtD
Gadoxetate—Swelling—Capecitabine—esophageal cancer	0.000341	0.00494	CcSEcCtD
Gadoxetate—ABCC4—Response to elevated platelet cytosolic Ca2+—CFL1—esophageal cancer	0.00034	0.00495	CbGpPWpGaD
Gadoxetate—ABCC3—NRF2 pathway—ADH7—esophageal cancer	0.000335	0.00488	CbGpPWpGaD
Gadoxetate—Oliguria—Methotrexate—esophageal cancer	0.000335	0.00485	CcSEcCtD
Gadoxetate—ABCC4—NRF2 pathway—SLC39A6—esophageal cancer	0.00033	0.00481	CbGpPWpGaD
Gadoxetate—ABCC2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.000329	0.00478	CbGpPWpGaD
Gadoxetate—Ulcer—Methotrexate—esophageal cancer	0.000327	0.00473	CcSEcCtD
Gadoxetate—Renal failure acute—Capecitabine—esophageal cancer	0.000326	0.00472	CcSEcCtD
Gadoxetate—Renal impairment—Capecitabine—esophageal cancer	0.000316	0.00458	CcSEcCtD
Gadoxetate—ABCC4—NRF2 pathway—ADH7—esophageal cancer	0.000315	0.00459	CbGpPWpGaD
Gadoxetate—ABCC2—ABC-family proteins mediated transport—ABCB1—esophageal cancer	0.000314	0.00457	CbGpPWpGaD
Gadoxetate—ABCC2—NRF2 pathway—PRDX1—esophageal cancer	0.000313	0.00455	CbGpPWpGaD
Gadoxetate—Acute coronary syndrome—Cisplatin—esophageal cancer	0.00031	0.00449	CcSEcCtD
Gadoxetate—Renal failure—Cisplatin—esophageal cancer	0.00031	0.00448	CcSEcCtD
Gadoxetate—Myocardial infarction—Cisplatin—esophageal cancer	0.000309	0.00447	CcSEcCtD
Gadoxetate—Cerebrovascular accident—Capecitabine—esophageal cancer	0.000307	0.00445	CcSEcCtD
Gadoxetate—Conjunctivitis—Cisplatin—esophageal cancer	0.000306	0.00443	CcSEcCtD
Gadoxetate—Face oedema—Capecitabine—esophageal cancer	0.000291	0.00421	CcSEcCtD
Gadoxetate—Irritability—Capecitabine—esophageal cancer	0.000287	0.00416	CcSEcCtD
Gadoxetate—Blood creatinine increased—Capecitabine—esophageal cancer	0.000282	0.00409	CcSEcCtD
Gadoxetate—Dehydration—Capecitabine—esophageal cancer	0.00028	0.00406	CcSEcCtD
Gadoxetate—ABCC2—NRF2 pathway—SLC39A6—esophageal cancer	0.000279	0.00405	CbGpPWpGaD
Gadoxetate—Connective tissue disorder—Cisplatin—esophageal cancer	0.000278	0.00402	CcSEcCtD
Gadoxetate—ABCC4—Platelet degranulation—HSPA5—esophageal cancer	0.000274	0.00399	CbGpPWpGaD
Gadoxetate—Hypokalaemia—Capecitabine—esophageal cancer	0.000274	0.00397	CcSEcCtD
Gadoxetate—Sepsis—Methotrexate—esophageal cancer	0.000268	0.00388	CcSEcCtD
Gadoxetate—ABCC2—NRF2 pathway—ADH7—esophageal cancer	0.000266	0.00387	CbGpPWpGaD
Gadoxetate—Cardiac disorder—Cisplatin—esophageal cancer	0.000262	0.0038	CcSEcCtD
Gadoxetate—Flushing—Cisplatin—esophageal cancer	0.000262	0.0038	CcSEcCtD
Gadoxetate—Abdominal distension—Capecitabine—esophageal cancer	0.000262	0.00379	CcSEcCtD
Gadoxetate—ABCC4—Response to elevated platelet cytosolic Ca2+—HSPA5—esophageal cancer	0.000261	0.0038	CbGpPWpGaD
Gadoxetate—Dysphagia—Capecitabine—esophageal cancer	0.00026	0.00377	CcSEcCtD
Gadoxetate—Bronchospasm—Capecitabine—esophageal cancer	0.000256	0.00371	CcSEcCtD
Gadoxetate—Immune system disorder—Cisplatin—esophageal cancer	0.000255	0.0037	CcSEcCtD
Gadoxetate—Mediastinal disorder—Cisplatin—esophageal cancer	0.000255	0.00369	CcSEcCtD
Gadoxetate—Sweating increased—Capecitabine—esophageal cancer	0.000254	0.00367	CcSEcCtD
Gadoxetate—Arrhythmia—Cisplatin—esophageal cancer	0.000253	0.00366	CcSEcCtD
Gadoxetate—Bronchitis—Capecitabine—esophageal cancer	0.00025	0.00362	CcSEcCtD
Gadoxetate—SLCO1B3—SLC-mediated transmembrane transport—SLC39A6—esophageal cancer	0.000245	0.00357	CbGpPWpGaD
Gadoxetate—ABCC3—NRF2 pathway—ABCC2—esophageal cancer	0.000244	0.00354	CbGpPWpGaD
Gadoxetate—Renal failure acute—Methotrexate—esophageal cancer	0.000243	0.00352	CcSEcCtD
Gadoxetate—Flatulence—Cisplatin—esophageal cancer	0.000242	0.00351	CcSEcCtD
Gadoxetate—Vision blurred—Cisplatin—esophageal cancer	0.000232	0.00336	CcSEcCtD
Gadoxetate—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.000232	0.00335	CcSEcCtD
Gadoxetate—Tremor—Cisplatin—esophageal cancer	0.000231	0.00334	CcSEcCtD
Gadoxetate—ABCC4—NRF2 pathway—ABCC2—esophageal cancer	0.000229	0.00333	CbGpPWpGaD
Gadoxetate—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000229	0.00331	CcSEcCtD
Gadoxetate—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000229	0.00331	CcSEcCtD
Gadoxetate—Ill-defined disorder—Cisplatin—esophageal cancer	0.000228	0.00331	CcSEcCtD
Gadoxetate—Renal failure—Capecitabine—esophageal cancer	0.000228	0.0033	CcSEcCtD
Gadoxetate—Myocardial infarction—Capecitabine—esophageal cancer	0.000228	0.00329	CcSEcCtD
Gadoxetate—ABCC3—NRF2 pathway—NFE2L2—esophageal cancer	0.000226	0.0033	CbGpPWpGaD
Gadoxetate—Conjunctivitis—Capecitabine—esophageal cancer	0.000226	0.00327	CcSEcCtD
Gadoxetate—SLCO1B3—SLC-mediated transmembrane transport—SLC30A7—esophageal cancer	0.000225	0.00327	CbGpPWpGaD
Gadoxetate—ABCC4—Ectoderm Differentiation—SOX2—esophageal cancer	0.000223	0.00324	CbGpPWpGaD
Gadoxetate—Malaise—Cisplatin—esophageal cancer	0.000222	0.00321	CcSEcCtD
Gadoxetate—Irritability—Methotrexate—esophageal cancer	0.000214	0.0031	CcSEcCtD
Gadoxetate—Convulsion—Cisplatin—esophageal cancer	0.000213	0.00309	CcSEcCtD
Gadoxetate—ABCC4—NRF2 pathway—NFE2L2—esophageal cancer	0.000213	0.0031	CbGpPWpGaD
Gadoxetate—Rhinitis—Capecitabine—esophageal cancer	0.000209	0.00302	CcSEcCtD
Gadoxetate—Anxiety—Cisplatin—esophageal cancer	0.000209	0.00302	CcSEcCtD
Gadoxetate—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000208	0.00301	CcSEcCtD
Gadoxetate—Hypoaesthesia—Capecitabine—esophageal cancer	0.000207	0.003	CcSEcCtD
Gadoxetate—Discomfort—Cisplatin—esophageal cancer	0.000207	0.003	CcSEcCtD
Gadoxetate—Connective tissue disorder—Capecitabine—esophageal cancer	0.000205	0.00296	CcSEcCtD
Gadoxetate—Anaphylactic shock—Cisplatin—esophageal cancer	0.000201	0.00291	CcSEcCtD
Gadoxetate—Oedema—Cisplatin—esophageal cancer	0.000201	0.00291	CcSEcCtD
Gadoxetate—Infection—Cisplatin—esophageal cancer	0.0002	0.00289	CcSEcCtD
Gadoxetate—Nervous system disorder—Cisplatin—esophageal cancer	0.000197	0.00285	CcSEcCtD
Gadoxetate—Tachycardia—Cisplatin—esophageal cancer	0.000196	0.00284	CcSEcCtD
Gadoxetate—ABCC4—Platelet activation, signaling and aggregation—PFN1—esophageal cancer	0.000195	0.00284	CbGpPWpGaD
Gadoxetate—Skin disorder—Cisplatin—esophageal cancer	0.000195	0.00282	CcSEcCtD
Gadoxetate—ABCC3—NRF2 pathway—CYP2A6—esophageal cancer	0.000195	0.00283	CbGpPWpGaD
Gadoxetate—ABCC4—Hemostasis—CAPZA1—esophageal cancer	0.000195	0.00283	CbGpPWpGaD
Gadoxetate—Hyperhidrosis—Cisplatin—esophageal cancer	0.000194	0.00281	CcSEcCtD
Gadoxetate—Cardiac disorder—Capecitabine—esophageal cancer	0.000193	0.0028	CcSEcCtD
Gadoxetate—Flushing—Capecitabine—esophageal cancer	0.000193	0.0028	CcSEcCtD
Gadoxetate—Anorexia—Cisplatin—esophageal cancer	0.000191	0.00277	CcSEcCtD
Gadoxetate—Angiopathy—Capecitabine—esophageal cancer	0.000189	0.00274	CcSEcCtD
Gadoxetate—Immune system disorder—Capecitabine—esophageal cancer	0.000188	0.00273	CcSEcCtD
Gadoxetate—Mediastinal disorder—Capecitabine—esophageal cancer	0.000188	0.00272	CcSEcCtD
Gadoxetate—Hypotension—Cisplatin—esophageal cancer	0.000188	0.00272	CcSEcCtD
Gadoxetate—Chills—Capecitabine—esophageal cancer	0.000187	0.00271	CcSEcCtD
Gadoxetate—Arrhythmia—Capecitabine—esophageal cancer	0.000186	0.0027	CcSEcCtD
Gadoxetate—ABCC4—NRF2 pathway—CYP2A6—esophageal cancer	0.000183	0.00266	CbGpPWpGaD
Gadoxetate—Paraesthesia—Cisplatin—esophageal cancer	0.00018	0.00261	CcSEcCtD
Gadoxetate—ABCC2—NRF2 pathway—NFE2L2—esophageal cancer	0.00018	0.00261	CbGpPWpGaD
Gadoxetate—Dyspnoea—Cisplatin—esophageal cancer	0.000179	0.00259	CcSEcCtD
Gadoxetate—Flatulence—Capecitabine—esophageal cancer	0.000179	0.00259	CcSEcCtD
Gadoxetate—Dysgeusia—Capecitabine—esophageal cancer	0.000178	0.00257	CcSEcCtD
Gadoxetate—Back pain—Capecitabine—esophageal cancer	0.000175	0.00254	CcSEcCtD
Gadoxetate—Decreased appetite—Cisplatin—esophageal cancer	0.000175	0.00253	CcSEcCtD
Gadoxetate—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000173	0.00251	CcSEcCtD
Gadoxetate—Vision blurred—Capecitabine—esophageal cancer	0.000171	0.00248	CcSEcCtD
Gadoxetate—Tremor—Capecitabine—esophageal cancer	0.00017	0.00246	CcSEcCtD
Gadoxetate—Renal failure—Methotrexate—esophageal cancer	0.00017	0.00246	CcSEcCtD
Gadoxetate—Ill-defined disorder—Capecitabine—esophageal cancer	0.000168	0.00244	CcSEcCtD
Gadoxetate—Conjunctivitis—Methotrexate—esophageal cancer	0.000168	0.00243	CcSEcCtD
Gadoxetate—Feeling abnormal—Cisplatin—esophageal cancer	0.000165	0.0024	CcSEcCtD
Gadoxetate—SLCO1B1—SLC-mediated transmembrane transport—SLC39A6—esophageal cancer	0.000165	0.0024	CbGpPWpGaD
Gadoxetate—Malaise—Capecitabine—esophageal cancer	0.000164	0.00237	CcSEcCtD
Gadoxetate—Vertigo—Capecitabine—esophageal cancer	0.000163	0.00236	CcSEcCtD
Gadoxetate—Syncope—Capecitabine—esophageal cancer	0.000163	0.00236	CcSEcCtD
Gadoxetate—Palpitations—Capecitabine—esophageal cancer	0.00016	0.00232	CcSEcCtD
Gadoxetate—Loss of consciousness—Capecitabine—esophageal cancer	0.000159	0.00231	CcSEcCtD
Gadoxetate—Body temperature increased—Cisplatin—esophageal cancer	0.000159	0.0023	CcSEcCtD
Gadoxetate—Cough—Capecitabine—esophageal cancer	0.000158	0.00229	CcSEcCtD
Gadoxetate—ABCC4—Platelet activation, signaling and aggregation—CFL1—esophageal cancer	0.000158	0.0023	CbGpPWpGaD
Gadoxetate—Chest pain—Capecitabine—esophageal cancer	0.000154	0.00224	CcSEcCtD
Gadoxetate—ABCC2—NRF2 pathway—CYP2A6—esophageal cancer	0.000154	0.00225	CbGpPWpGaD
Gadoxetate—Anxiety—Capecitabine—esophageal cancer	0.000154	0.00223	CcSEcCtD
Gadoxetate—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000153	0.00222	CcSEcCtD
Gadoxetate—Discomfort—Capecitabine—esophageal cancer	0.000153	0.00221	CcSEcCtD
Gadoxetate—Dry mouth—Capecitabine—esophageal cancer	0.000151	0.00219	CcSEcCtD
Gadoxetate—SLCO1B1—SLC-mediated transmembrane transport—SLC30A7—esophageal cancer	0.000151	0.00219	CbGpPWpGaD
Gadoxetate—ABCC4—Platelet activation, signaling and aggregation—GNG7—esophageal cancer	0.000149	0.00217	CbGpPWpGaD
Gadoxetate—Oedema—Capecitabine—esophageal cancer	0.000148	0.00214	CcSEcCtD
Gadoxetate—Hypersensitivity—Cisplatin—esophageal cancer	0.000148	0.00214	CcSEcCtD
Gadoxetate—SLCO1B3—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000147	0.00214	CbGpPWpGaD
Gadoxetate—Infection—Capecitabine—esophageal cancer	0.000147	0.00213	CcSEcCtD
Gadoxetate—Shock—Capecitabine—esophageal cancer	0.000146	0.00211	CcSEcCtD
Gadoxetate—Nervous system disorder—Capecitabine—esophageal cancer	0.000145	0.0021	CcSEcCtD
Gadoxetate—Tachycardia—Capecitabine—esophageal cancer	0.000144	0.00209	CcSEcCtD
Gadoxetate—Asthenia—Cisplatin—esophageal cancer	0.000144	0.00209	CcSEcCtD
Gadoxetate—Cardiac disorder—Methotrexate—esophageal cancer	0.000144	0.00208	CcSEcCtD
Gadoxetate—Skin disorder—Capecitabine—esophageal cancer	0.000144	0.00208	CcSEcCtD
Gadoxetate—Hyperhidrosis—Capecitabine—esophageal cancer	0.000143	0.00207	CcSEcCtD
Gadoxetate—Anorexia—Capecitabine—esophageal cancer	0.000141	0.00204	CcSEcCtD
Gadoxetate—Angiopathy—Methotrexate—esophageal cancer	0.000141	0.00204	CcSEcCtD
Gadoxetate—Immune system disorder—Methotrexate—esophageal cancer	0.00014	0.00203	CcSEcCtD
Gadoxetate—SLCO1B3—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.00014	0.00204	CbGpPWpGaD
Gadoxetate—Mediastinal disorder—Methotrexate—esophageal cancer	0.00014	0.00202	CcSEcCtD
Gadoxetate—Chills—Methotrexate—esophageal cancer	0.000139	0.00202	CcSEcCtD
Gadoxetate—ABCC3—Fluoropyrimidine Activity—TP53—esophageal cancer	0.000138	0.00201	CbGpPWpGaD
Gadoxetate—Hypotension—Capecitabine—esophageal cancer	0.000138	0.002	CcSEcCtD
Gadoxetate—Diarrhoea—Cisplatin—esophageal cancer	0.000137	0.00199	CcSEcCtD
Gadoxetate—ABCC3—NRF2 pathway—TGFBR2—esophageal cancer	0.000137	0.00199	CbGpPWpGaD
Gadoxetate—ABCC3—NRF2 pathway—HMOX1—esophageal cancer	0.000135	0.00196	CbGpPWpGaD
Gadoxetate—Paraesthesia—Capecitabine—esophageal cancer	0.000133	0.00192	CcSEcCtD
Gadoxetate—ABCC3—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000133	0.00193	CbGpPWpGaD
Gadoxetate—Dysgeusia—Methotrexate—esophageal cancer	0.000132	0.00191	CcSEcCtD
Gadoxetate—Dyspnoea—Capecitabine—esophageal cancer	0.000132	0.00191	CcSEcCtD
Gadoxetate—SLCO1B3—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.000132	0.00191	CbGpPWpGaD
Gadoxetate—Back pain—Methotrexate—esophageal cancer	0.000131	0.00189	CcSEcCtD
Gadoxetate—ABCC4—Fluoropyrimidine Activity—TP53—esophageal cancer	0.00013	0.00189	CbGpPWpGaD
Gadoxetate—ABCC4—Hemostasis—ATP1B2—esophageal cancer	0.000129	0.00188	CbGpPWpGaD
Gadoxetate—Decreased appetite—Capecitabine—esophageal cancer	0.000129	0.00186	CcSEcCtD
Gadoxetate—ABCC4—NRF2 pathway—TGFBR2—esophageal cancer	0.000128	0.00187	CbGpPWpGaD
Gadoxetate—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000128	0.00185	CcSEcCtD
Gadoxetate—Vomiting—Cisplatin—esophageal cancer	0.000128	0.00185	CcSEcCtD
Gadoxetate—Fatigue—Capecitabine—esophageal cancer	0.000128	0.00185	CcSEcCtD
Gadoxetate—Vision blurred—Methotrexate—esophageal cancer	0.000127	0.00184	CcSEcCtD
Gadoxetate—ABCC4—Ectoderm Differentiation—SMAD4—esophageal cancer	0.000127	0.00185	CbGpPWpGaD
Gadoxetate—ABCC4—NRF2 pathway—HMOX1—esophageal cancer	0.000127	0.00184	CbGpPWpGaD
Gadoxetate—Rash—Cisplatin—esophageal cancer	0.000127	0.00183	CcSEcCtD
Gadoxetate—Constipation—Capecitabine—esophageal cancer	0.000127	0.00183	CcSEcCtD
Gadoxetate—Dermatitis—Cisplatin—esophageal cancer	0.000126	0.00183	CcSEcCtD
Gadoxetate—ABCC3—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.000126	0.00184	CbGpPWpGaD
Gadoxetate—Ill-defined disorder—Methotrexate—esophageal cancer	0.000125	0.00181	CcSEcCtD
Gadoxetate—SLCO1B3—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.000125	0.00182	CbGpPWpGaD
Gadoxetate—Feeling abnormal—Capecitabine—esophageal cancer	0.000122	0.00177	CcSEcCtD
Gadoxetate—Malaise—Methotrexate—esophageal cancer	0.000122	0.00176	CcSEcCtD
Gadoxetate—ABCC4—Platelet activation, signaling and aggregation—HSPA5—esophageal cancer	0.000122	0.00177	CbGpPWpGaD
Gadoxetate—Vertigo—Methotrexate—esophageal cancer	0.000121	0.00176	CcSEcCtD
Gadoxetate—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000121	0.00175	CcSEcCtD
Gadoxetate—Nausea—Cisplatin—esophageal cancer	0.000119	0.00173	CcSEcCtD
Gadoxetate—SLCO1B3—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.000119	0.00173	CbGpPWpGaD
Gadoxetate—ABCC4—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.000119	0.00173	CbGpPWpGaD
Gadoxetate—ABCC3—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.000119	0.00173	CbGpPWpGaD
Gadoxetate—Cough—Methotrexate—esophageal cancer	0.000118	0.00171	CcSEcCtD
Gadoxetate—Urticaria—Capecitabine—esophageal cancer	0.000118	0.0017	CcSEcCtD
Gadoxetate—Body temperature increased—Capecitabine—esophageal cancer	0.000117	0.00169	CcSEcCtD
Gadoxetate—Abdominal pain—Capecitabine—esophageal cancer	0.000117	0.00169	CcSEcCtD
Gadoxetate—Convulsion—Methotrexate—esophageal cancer	0.000117	0.00169	CcSEcCtD
Gadoxetate—ABCC4—Hemostasis—DOCK2—esophageal cancer	0.000117	0.0017	CbGpPWpGaD
Gadoxetate—Chest pain—Methotrexate—esophageal cancer	0.000115	0.00166	CcSEcCtD
Gadoxetate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000114	0.00165	CcSEcCtD
Gadoxetate—SLCO1B3—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.000114	0.00166	CbGpPWpGaD
Gadoxetate—SLCO1B3—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.000114	0.00166	CbGpPWpGaD
Gadoxetate—Discomfort—Methotrexate—esophageal cancer	0.000114	0.00164	CcSEcCtD
Gadoxetate—ABCC3—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.000113	0.00164	CbGpPWpGaD
Gadoxetate—ABCC4—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.000112	0.00162	CbGpPWpGaD
Gadoxetate—Anaphylactic shock—Methotrexate—esophageal cancer	0.00011	0.0016	CcSEcCtD
Gadoxetate—Infection—Methotrexate—esophageal cancer	0.000109	0.00159	CcSEcCtD
Gadoxetate—Hypersensitivity—Capecitabine—esophageal cancer	0.000109	0.00158	CcSEcCtD
Gadoxetate—ABCC2—NRF2 pathway—TGFBR2—esophageal cancer	0.000108	0.00158	CbGpPWpGaD
Gadoxetate—Nervous system disorder—Methotrexate—esophageal cancer	0.000108	0.00156	CcSEcCtD
Gadoxetate—ABCC3—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.000107	0.00156	CbGpPWpGaD
Gadoxetate—Skin disorder—Methotrexate—esophageal cancer	0.000107	0.00155	CcSEcCtD
Gadoxetate—ABCC2—NRF2 pathway—HMOX1—esophageal cancer	0.000107	0.00155	CbGpPWpGaD
Gadoxetate—Hyperhidrosis—Methotrexate—esophageal cancer	0.000107	0.00154	CcSEcCtD
Gadoxetate—Asthenia—Capecitabine—esophageal cancer	0.000106	0.00154	CcSEcCtD
Gadoxetate—ABCC4—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.000106	0.00154	CbGpPWpGaD
Gadoxetate—Anorexia—Methotrexate—esophageal cancer	0.000105	0.00152	CcSEcCtD
Gadoxetate—Pruritus—Capecitabine—esophageal cancer	0.000105	0.00152	CcSEcCtD
Gadoxetate—Hypotension—Methotrexate—esophageal cancer	0.000103	0.00149	CcSEcCtD
Gadoxetate—ABCC3—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.000103	0.0015	CbGpPWpGaD
Gadoxetate—ABCC3—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.000103	0.0015	CbGpPWpGaD
Gadoxetate—Diarrhoea—Capecitabine—esophageal cancer	0.000101	0.00147	CcSEcCtD
Gadoxetate—ABCC4—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.000101	0.00147	CbGpPWpGaD
Gadoxetate—ABCC4—Hemostasis—PFN1—esophageal cancer	0.000101	0.00146	CbGpPWpGaD
Gadoxetate—ABCC2—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.0001	0.00146	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	9.94e-05	0.00145	CbGpPWpGaD
Gadoxetate—Paraesthesia—Methotrexate—esophageal cancer	9.9e-05	0.00143	CcSEcCtD
Gadoxetate—SLCO1B1—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	9.89e-05	0.00144	CbGpPWpGaD
Gadoxetate—Dyspnoea—Methotrexate—esophageal cancer	9.82e-05	0.00142	CcSEcCtD
Gadoxetate—Dizziness—Capecitabine—esophageal cancer	9.79e-05	0.00142	CcSEcCtD
Gadoxetate—ABCC4—Transmembrane transport of small molecules—ATP4A—esophageal cancer	9.68e-05	0.00141	CbGpPWpGaD
Gadoxetate—ABCC4—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	9.68e-05	0.00141	CbGpPWpGaD
Gadoxetate—Decreased appetite—Methotrexate—esophageal cancer	9.58e-05	0.00139	CcSEcCtD
Gadoxetate—Gastrointestinal disorder—Methotrexate—esophageal cancer	9.51e-05	0.00138	CcSEcCtD
Gadoxetate—Fatigue—Methotrexate—esophageal cancer	9.5e-05	0.00138	CcSEcCtD
Gadoxetate—ABCC2—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	9.41e-05	0.00137	CbGpPWpGaD
Gadoxetate—Vomiting—Capecitabine—esophageal cancer	9.41e-05	0.00136	CcSEcCtD
Gadoxetate—SLCO1B1—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	9.4e-05	0.00137	CbGpPWpGaD
Gadoxetate—Rash—Capecitabine—esophageal cancer	9.33e-05	0.00135	CcSEcCtD
Gadoxetate—Dermatitis—Capecitabine—esophageal cancer	9.32e-05	0.00135	CcSEcCtD
Gadoxetate—Headache—Capecitabine—esophageal cancer	9.27e-05	0.00134	CcSEcCtD
Gadoxetate—Feeling abnormal—Methotrexate—esophageal cancer	9.08e-05	0.00131	CcSEcCtD
Gadoxetate—Gastrointestinal pain—Methotrexate—esophageal cancer	9.01e-05	0.0013	CcSEcCtD
Gadoxetate—ABCC3—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	8.97e-05	0.00131	CbGpPWpGaD
Gadoxetate—ABCC2—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	8.92e-05	0.0013	CbGpPWpGaD
Gadoxetate—SLCO1B1—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	8.84e-05	0.00129	CbGpPWpGaD
Gadoxetate—Nausea—Capecitabine—esophageal cancer	8.79e-05	0.00127	CcSEcCtD
Gadoxetate—Urticaria—Methotrexate—esophageal cancer	8.75e-05	0.00127	CcSEcCtD
Gadoxetate—Body temperature increased—Methotrexate—esophageal cancer	8.71e-05	0.00126	CcSEcCtD
Gadoxetate—Abdominal pain—Methotrexate—esophageal cancer	8.71e-05	0.00126	CcSEcCtD
Gadoxetate—SLCO1B3—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	8.68e-05	0.00126	CbGpPWpGaD
Gadoxetate—SLCO1B3—Transmembrane transport of small molecules—ABCC2—esophageal cancer	8.65e-05	0.00126	CbGpPWpGaD
Gadoxetate—ABCC2—Transmembrane transport of small molecules—AQP3—esophageal cancer	8.51e-05	0.00124	CbGpPWpGaD
Gadoxetate—SLCO1B1—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	8.38e-05	0.00122	CbGpPWpGaD
Gadoxetate—ABCC2—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	8.16e-05	0.00119	CbGpPWpGaD
Gadoxetate—ABCC2—Transmembrane transport of small molecules—ATP4A—esophageal cancer	8.16e-05	0.00119	CbGpPWpGaD
Gadoxetate—ABCC4—Hemostasis—CFL1—esophageal cancer	8.16e-05	0.00119	CbGpPWpGaD
Gadoxetate—Hypersensitivity—Methotrexate—esophageal cancer	8.12e-05	0.00118	CcSEcCtD
Gadoxetate—SLCO1B1—Transmembrane transport of small molecules—AQP3—esophageal cancer	8e-05	0.00116	CbGpPWpGaD
Gadoxetate—Asthenia—Methotrexate—esophageal cancer	7.91e-05	0.00114	CcSEcCtD
Gadoxetate—SLCO1B3—Transmembrane transport of small molecules—GNG7—esophageal cancer	7.85e-05	0.00114	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	7.83e-05	0.00114	CbGpPWpGaD
Gadoxetate—ABCC3—Transmembrane transport of small molecules—ABCC2—esophageal cancer	7.8e-05	0.00114	CbGpPWpGaD
Gadoxetate—Pruritus—Methotrexate—esophageal cancer	7.8e-05	0.00113	CcSEcCtD
Gadoxetate—SLCO1B3—Metabolism—SLC52A3—esophageal cancer	7.71e-05	0.00112	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—BLVRB—esophageal cancer	7.71e-05	0.00112	CbGpPWpGaD
Gadoxetate—ABCC4—Hemostasis—GNG7—esophageal cancer	7.69e-05	0.00112	CbGpPWpGaD
Gadoxetate—SLCO1B1—Transmembrane transport of small molecules—ATP4A—esophageal cancer	7.67e-05	0.00112	CbGpPWpGaD
Gadoxetate—SLCO1B1—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	7.67e-05	0.00112	CbGpPWpGaD
Gadoxetate—Diarrhoea—Methotrexate—esophageal cancer	7.54e-05	0.00109	CcSEcCtD
Gadoxetate—ABCC4—Transmembrane transport of small molecules—ABCC2—esophageal cancer	7.34e-05	0.00107	CbGpPWpGaD
Gadoxetate—Dizziness—Methotrexate—esophageal cancer	7.29e-05	0.00106	CcSEcCtD
Gadoxetate—ABCC3—Transmembrane transport of small molecules—GNG7—esophageal cancer	7.08e-05	0.00103	CbGpPWpGaD
Gadoxetate—Vomiting—Methotrexate—esophageal cancer	7.01e-05	0.00101	CcSEcCtD
Gadoxetate—ABCC3—Metabolism—BLVRB—esophageal cancer	6.96e-05	0.00101	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—SLC52A3—esophageal cancer	6.96e-05	0.00101	CbGpPWpGaD
Gadoxetate—Rash—Methotrexate—esophageal cancer	6.95e-05	0.00101	CcSEcCtD
Gadoxetate—Dermatitis—Methotrexate—esophageal cancer	6.94e-05	0.00101	CcSEcCtD
Gadoxetate—Headache—Methotrexate—esophageal cancer	6.9e-05	0.001	CcSEcCtD
Gadoxetate—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	6.89e-05	0.001	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	6.68e-05	0.000972	CbGpPWpGaD
Gadoxetate—ABCC4—Transmembrane transport of small molecules—GNG7—esophageal cancer	6.66e-05	0.000968	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—CA1—esophageal cancer	6.56e-05	0.000954	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—SLC10A2—esophageal cancer	6.56e-05	0.000954	CbGpPWpGaD
Gadoxetate—Nausea—Methotrexate—esophageal cancer	6.55e-05	0.000948	CcSEcCtD
Gadoxetate—ABCC4—Hemostasis—HSPA5—esophageal cancer	6.27e-05	0.000912	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	6.22e-05	0.000905	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—CA2—esophageal cancer	6e-05	0.000872	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—CA1—esophageal cancer	5.91e-05	0.000861	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—SLC10A2—esophageal cancer	5.91e-05	0.000861	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	5.86e-05	0.000853	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	5.83e-05	0.000848	CbGpPWpGaD
Gadoxetate—SLCO1B1—Transmembrane transport of small molecules—ABCC2—esophageal cancer	5.81e-05	0.000845	CbGpPWpGaD
Gadoxetate—ABCC2—Transmembrane transport of small molecules—GNG7—esophageal cancer	5.61e-05	0.000817	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—ADH7—esophageal cancer	5.57e-05	0.000811	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—PLCE1—esophageal cancer	5.57e-05	0.000811	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	5.51e-05	0.000802	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—CA2—esophageal cancer	5.41e-05	0.000787	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	5.29e-05	0.000769	CbGpPWpGaD
Gadoxetate—SLCO1B1—Transmembrane transport of small molecules—GNG7—esophageal cancer	5.27e-05	0.000767	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—BLVRB—esophageal cancer	5.18e-05	0.000754	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—SLC52A3—esophageal cancer	5.18e-05	0.000754	CbGpPWpGaD
Gadoxetate—ABCC4—Ectoderm Differentiation—MYC—esophageal cancer	5.04e-05	0.000734	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—PLCE1—esophageal cancer	5.03e-05	0.000732	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—ADH7—esophageal cancer	5.03e-05	0.000732	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	4.97e-05	0.000723	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—ADH1B—esophageal cancer	4.89e-05	0.000711	CbGpPWpGaD
Gadoxetate—SLCO1B3—Transmembrane transport of small molecules—HMOX1—esophageal cancer	4.78e-05	0.000696	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—TYMP—esophageal cancer	4.67e-05	0.00068	CbGpPWpGaD
Gadoxetate—ABCC4—Hemostasis—ABL1—esophageal cancer	4.64e-05	0.000676	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	4.63e-05	0.000674	CbGpPWpGaD
Gadoxetate—SLCO1B3—Transmembrane transport of small molecules—ABCB1—esophageal cancer	4.59e-05	0.000668	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—CYP26A1—esophageal cancer	4.54e-05	0.000661	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—ALOX15—esophageal cancer	4.43e-05	0.000644	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—ADH1B—esophageal cancer	4.41e-05	0.000642	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—CA1—esophageal cancer	4.4e-05	0.000641	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—SLC10A2—esophageal cancer	4.4e-05	0.000641	CbGpPWpGaD
Gadoxetate—ABCC3—Transmembrane transport of small molecules—HMOX1—esophageal cancer	4.31e-05	0.000628	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—TPI1—esophageal cancer	4.22e-05	0.000615	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—GSTO1—esophageal cancer	4.22e-05	0.000615	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—TYMP—esophageal cancer	4.21e-05	0.000613	CbGpPWpGaD
Gadoxetate—ABCC3—Transmembrane transport of small molecules—ABCB1—esophageal cancer	4.14e-05	0.000602	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—CYP26A1—esophageal cancer	4.1e-05	0.000597	CbGpPWpGaD
Gadoxetate—ABCC4—Transmembrane transport of small molecules—HMOX1—esophageal cancer	4.06e-05	0.00059	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—ALDOB—esophageal cancer	4.05e-05	0.000589	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—CA2—esophageal cancer	4.03e-05	0.000586	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—ALOX15—esophageal cancer	4e-05	0.000581	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	3.94e-05	0.000573	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—GAPDH—esophageal cancer	3.9e-05	0.000567	CbGpPWpGaD
Gadoxetate—ABCC4—Transmembrane transport of small molecules—ABCB1—esophageal cancer	3.89e-05	0.000566	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—CRABP1—esophageal cancer	3.86e-05	0.000562	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—TPI1—esophageal cancer	3.81e-05	0.000555	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—GSTO1—esophageal cancer	3.81e-05	0.000555	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—ADH7—esophageal cancer	3.74e-05	0.000545	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—PLCE1—esophageal cancer	3.74e-05	0.000545	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	3.7e-05	0.000539	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—GNG7—esophageal cancer	3.67e-05	0.000535	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—ALDOB—esophageal cancer	3.65e-05	0.000532	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—GAPDH—esophageal cancer	3.52e-05	0.000512	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—CRABP1—esophageal cancer	3.49e-05	0.000507	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—ALDH2—esophageal cancer	3.44e-05	0.000501	CbGpPWpGaD
Gadoxetate—ABCC2—Transmembrane transport of small molecules—HMOX1—esophageal cancer	3.42e-05	0.000498	CbGpPWpGaD
Gadoxetate—ABCC4—Hemostasis—NOS2—esophageal cancer	3.35e-05	0.000487	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—GNG7—esophageal cancer	3.32e-05	0.000482	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—ADH1B—esophageal cancer	3.28e-05	0.000478	CbGpPWpGaD
Gadoxetate—ABCC2—Transmembrane transport of small molecules—ABCB1—esophageal cancer	3.28e-05	0.000478	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—GSTT1—esophageal cancer	3.28e-05	0.000477	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—CYP2A6—esophageal cancer	3.24e-05	0.000471	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	3.23e-05	0.000469	CbGpPWpGaD
Gadoxetate—SLCO1B1—Transmembrane transport of small molecules—HMOX1—esophageal cancer	3.21e-05	0.000467	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—TYMP—esophageal cancer	3.14e-05	0.000457	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—ALDH2—esophageal cancer	3.11e-05	0.000452	CbGpPWpGaD
Gadoxetate—SLCO1B1—Transmembrane transport of small molecules—ABCB1—esophageal cancer	3.08e-05	0.000449	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—ENO1—esophageal cancer	3.07e-05	0.000447	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—PTGS1—esophageal cancer	3.07e-05	0.000447	CbGpPWpGaD
Gadoxetate—SLCO1B3—Transmembrane transport of small molecules—CREBBP—esophageal cancer	3.07e-05	0.000446	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—CYP26A1—esophageal cancer	3.05e-05	0.000444	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—PSME1—esophageal cancer	3.02e-05	0.00044	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—PSME2—esophageal cancer	3.02e-05	0.00044	CbGpPWpGaD
Gadoxetate—ABCC4—Hemostasis—CREBBP—esophageal cancer	3.01e-05	0.000437	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—ALOX15—esophageal cancer	2.98e-05	0.000433	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—GSTT1—esophageal cancer	2.96e-05	0.00043	CbGpPWpGaD
Gadoxetate—ABCC4—Platelet activation, signaling and aggregation—PIK3CA—esophageal cancer	2.94e-05	0.000427	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—CYP2A6—esophageal cancer	2.92e-05	0.000425	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.91e-05	0.000423	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—GSTO1—esophageal cancer	2.84e-05	0.000413	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—TPI1—esophageal cancer	2.84e-05	0.000413	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—PTGS1—esophageal cancer	2.77e-05	0.000403	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—ENO1—esophageal cancer	2.77e-05	0.000403	CbGpPWpGaD
Gadoxetate—ABCC3—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.77e-05	0.000403	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—PSME2—esophageal cancer	2.73e-05	0.000397	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—PSME1—esophageal cancer	2.73e-05	0.000397	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—ALDOB—esophageal cancer	2.72e-05	0.000396	CbGpPWpGaD
Gadoxetate—ABCC4—Hemostasis—NOS3—esophageal cancer	2.69e-05	0.000392	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.64e-05	0.000384	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—GAPDH—esophageal cancer	2.62e-05	0.000381	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—CYP1B1—esophageal cancer	2.61e-05	0.00038	CbGpPWpGaD
Gadoxetate—ABCC4—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.6e-05	0.000379	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—CRABP1—esophageal cancer	2.6e-05	0.000378	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—GNG7—esophageal cancer	2.47e-05	0.000359	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—CYP19A1—esophageal cancer	2.45e-05	0.000357	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	2.38e-05	0.000347	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—CYP1B1—esophageal cancer	2.35e-05	0.000343	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—ALDH2—esophageal cancer	2.31e-05	0.000337	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—HMOX1—esophageal cancer	2.24e-05	0.000326	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—CYP19A1—esophageal cancer	2.21e-05	0.000322	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—GSTT1—esophageal cancer	2.2e-05	0.00032	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.2e-05	0.00032	CbGpPWpGaD
Gadoxetate—ABCC2—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.19e-05	0.000319	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—CYP2A6—esophageal cancer	2.18e-05	0.000317	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	2.17e-05	0.000315	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—ABCB1—esophageal cancer	2.15e-05	0.000313	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—PTGS1—esophageal cancer	2.06e-05	0.0003	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—ENO1—esophageal cancer	2.06e-05	0.0003	CbGpPWpGaD
Gadoxetate—SLCO1B1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	2.06e-05	0.0003	CbGpPWpGaD
Gadoxetate—ABCC4—Hemostasis—EP300—esophageal cancer	2.05e-05	0.000298	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—PSME2—esophageal cancer	2.03e-05	0.000296	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—PSME1—esophageal cancer	2.03e-05	0.000296	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—HMOX1—esophageal cancer	2.02e-05	0.000294	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.98e-05	0.000288	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—ABCB1—esophageal cancer	1.94e-05	0.000282	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	1.77e-05	0.000258	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—CYP1B1—esophageal cancer	1.75e-05	0.000255	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—CYP19A1—esophageal cancer	1.65e-05	0.00024	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.62e-05	0.000236	CbGpPWpGaD
Gadoxetate—ABCC4—Hemostasis—PIK3CA—esophageal cancer	1.51e-05	0.00022	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—HMOX1—esophageal cancer	1.5e-05	0.000219	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	1.48e-05	0.000215	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.47e-05	0.000213	CbGpPWpGaD
Gadoxetate—ABCC4—Hemostasis—TP53—esophageal cancer	1.46e-05	0.000213	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—ABCB1—esophageal cancer	1.44e-05	0.00021	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—CREBBP—esophageal cancer	1.44e-05	0.000209	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—CREBBP—esophageal cancer	1.3e-05	0.000189	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—NOS3—esophageal cancer	1.29e-05	0.000187	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—PTGS2—esophageal cancer	1.18e-05	0.000171	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—NOS3—esophageal cancer	1.16e-05	0.000169	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.09e-05	0.000159	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—PTGS2—esophageal cancer	1.06e-05	0.000154	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—EP300—esophageal cancer	9.78e-06	0.000142	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—CREBBP—esophageal cancer	9.65e-06	0.00014	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—EP300—esophageal cancer	8.83e-06	0.000128	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—NOS3—esophageal cancer	8.64e-06	0.000126	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—PTGS2—esophageal cancer	7.9e-06	0.000115	CbGpPWpGaD
Gadoxetate—SLCO1B3—Metabolism—PIK3CA—esophageal cancer	7.24e-06	0.000105	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—EP300—esophageal cancer	6.57e-06	9.56e-05	CbGpPWpGaD
Gadoxetate—ABCC3—Metabolism—PIK3CA—esophageal cancer	6.53e-06	9.5e-05	CbGpPWpGaD
Gadoxetate—SLCO1B1—Metabolism—PIK3CA—esophageal cancer	4.86e-06	7.07e-05	CbGpPWpGaD
